Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - Chongqing Zhifei Biological Products

Next Previous
Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Chongqing Zhifei Biological Products

Alternative Names: A, C, Y, W135 meningococcal polysaccharide conjugate vaccine; Menwaycon

Latest Information Update: 11 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Zhifei Biological Products
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 11 Feb 2022 Meningococcal vaccine groups A C Y W-135 conjugate development is ongoing China (NCT05229536)
  • 21 Nov 2019 Chongqing Zhifei Biological Products completes a phase II trial in Meningococcal group A, C, Y, W-135 infections (Prevention) in China (IM) in November 2019(NCT05229536)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Meningococcal-group-A-infections(Prevention, In volunteers) in China (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top